FGF R2 (IIIc)

FGF R2 (IIIc) Overview

English NameFibroblast growth factor receptor 2Approved Drugs9
Drugs in Clinical Trials30Target SynonymEC:2.7.10.1,EC 2.7.10,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,EC 2.7.10.1,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,Receptor, Fibroblast Growth Factor, Type 2
Highest Development StageApproved
English NameFibroblast growth factor receptor 2
Target SynonymEC:2.7.10.1,EC 2.7.10,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,EC 2.7.10.1,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,Receptor, Fibroblast Growth Factor, Type 2
Approved Drugs9
Drugs in Clinical Trials30
Highest Development StageApproved

FGF R2 (IIIc) Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
FGC-H5225
Human
HEK293
Human FGF R2 (IIIc) protein, His Tag (MALS verified)
Total: 1
  • 1

FGF R2 (IIIc) Background

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

FGF R2 (IIIc) Synonyms

FGF R2 (IIIc),FGFR2C,FGFR2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
InfigratinibBGJ-398 phosphate; BGJ-398; NVP-BGJ398; BBP-831; KK8398Phase 3 ClinicalNovartis Pharma AgAchondroplasia; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Hematologic Neoplasms; Nasopharyngeal Neoplasms; Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Rectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
SC-0011SC-0011Phase 3 ClinicalShijiazhuang Zhikang Hongren New Drug Development Co LtdCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms
Details
ZoligratinibCH-5183284; FF-284; Debio-1347Phase 2 ClinicalChugai Pharmaceutical Co LtdBreast Neoplasms; Solid tumours
Details
AUR-109ODM-203; AUR-109Phase 2 ClinicalOrion CorpBreast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pulmonary Fibrosis; Solid tumours; Urinary Bladder Neoplasms
Details
LucitanibS-80881; AL-3810; CO-3810; E-3810; S-80881-2Phase 2 ClinicalAdvenchen Laboratories Nanjing LtdBreast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thymus Neoplasms
Details
RogaratinibBAY-1163877Phase 2 ClinicalBayer AGBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms
Details
FexagratinibAZD4547; AZD-4547; ABSK-091; ABSK091Phase 2 ClinicalAstrazeneca PlcAdenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Foodborne Diseases; Gastrointestinal Diseases; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
DerazantinibARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087Phase 2 ClinicalArqule IncBiliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Transitional Cell; Cholangiocarcinoma; Solid tumours; Stomach Neoplasms; Urogenital Neoplasms
Details
Inhaled Nintedanib – dry powder (Avalyn Pharma)AP02; AP 02 DP; AP-02; AP02-DPPhase 2 ClinicalAvalyn Pharma IncIdiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Respiratory Tract Diseases
Details
3HP-28273HP-2827; 3HP2827Phase 2 Clinical3H (Suzhou) Pharmaceuticals Co LtdNeoplasms; Solid tumours
Details
CGT-4859CGT4859; CGT-4859Phase 2 ClinicalCogent Biosciences IncCholangiocarcinoma; Neoplasms; Solid tumours
Details
ABSK-061ABSK061Phase 2 ClinicalABbisko Therapeutics Co LtdAchondroplasia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Solid tumours
Details
PZH-2111PZH2111; PZH-2111Phase 2 ClinicalZhangzhou Pientzehuang Pharmaceutical Co LtdCholangiocarcinoma; Solid tumours
Details
GunagratinibICP-192Phase 2 ClinicalBeijing Tiancheng Pharmaceutical Technology Co LtdBiliary Tract Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Head and Neck Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
BPI-17509BPI-17509Phase 1 ClinicalBetta Pharmaceuticals Co LtdSolid tumours
Details
HH1853D-185; 3-D185; HH-185; 3D185Phase 1 ClinicalShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon IncSolid tumours
Details
nintedanib (Avalyn Pharma)Phase 1 ClinicalAvalyn Pharma IncIdiopathic Pulmonary Fibrosis; Pulmonary Fibrosis
Details
SIM-0686SCR-A002; SIM-0686Phase 1 ClinicalHainan Xiansheng Re Ming Pharmaceutical Co LtdNeoplasm Metastasis; Solid tumours
Details
TYRA-200TYRA200; TYRA-200Phase 1 ClinicalTyra Biosciences IncBile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Solid tumours
Details
ASN-8639ASN-8639; ASN8639Phase 1 ClinicalAsieris Pharmaceuticals LtdSolid tumours
Details
Nintedanib Esylate Inhalation Powder(Cspc)Phase 1 ClinicalCspc-Nbp Pharmaceutical Co LtdIdiopathic Pulmonary Fibrosis; Pulmonary Fibrosis
Details
TQB-2210TQB-2210; TQB2210Phase 1 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupNeoplasms
Details
HWS-116HWS116; HWS-116Phase 1 ClinicalWuhan Humanwell Innovative Drug Research and Development Center Co LtdSolid tumours
Details
KNT-0916KNT0916; KNT-0916Phase 1 ClinicalGuangzhou KinoTech Biopharmaceutical Technology Co LtdNeoplasm Metastasis; Solid tumours
Details
BG-C137BG-C137Phase 1 ClinicalBeOne Medicines LtdGastrointestinal Neoplasms; Solid tumours
Details
ACE-16229210ACE-16229210; ACE16229210Phase 1 ClinicalAcerand Therapeutics (Shanghai) LtdSolid tumours
Details
MNKD-201MNKD-201; MKND-201Phase 1 ClinicalMannKind CorpIdiopathic Pulmonary Fibrosis
Details
TT-00434TT-00434Phase 1 ClinicalTransThera Sciences (Nanjing) IncSolid tumours; Urinary Bladder Neoplasms
Details
ABSK-121ABSK121-NX; ABSK121Phase 1 ClinicalABbisko Therapeutics Co LtdSolid tumours
Details
CPL-304110CPL-304110; CPL-304-110Phase 1 ClinicalCelon Pharma SaCarcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Sarcoma; Stomach Neoplasms; Urinary Bladder Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Anlotinib DihydrochlorideAL-3818ApprovedAdvenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd福可维Mainland ChinaCarcinoma, Non-Small-Cell LungJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd2018-05-08Bile Duct Diseases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Craniopharyngioma; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Head and Neck Neoplasms; Hepatic Insufficiency; Leiomyosarcoma; Liver Dysfunction; Lung Diseases, Interstitial; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Medullary thyroid cancer (MTC); Melanoma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Neuroendocrine Tumors; Osteoma; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Sarcoma, Alveolar Soft Part; Sarcoma, Synovial; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thoracic Neoplasms; Thyroid Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms
Details
Lenvatinib MesilateE-7080; MK-7902; ER-203492-00ApprovedEisai Co LtdKisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛United StatesThyroid NeoplasmsEisai Inc2015-02-13Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Hepatic Insufficiency; Liver Diseases; Liver Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Renal Insufficiency; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Uterine Cervical Neoplasms
Details
RegorafenibDAST; BAY-73-4506ApprovedBayer AGStivarga, ResihanceUnited StatesColorectal NeoplasmsBayer Healthcare Pharmaceuticals Inc2012-09-27Adenocarcinoma; Adenoma; Bile Duct Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Hemangiosarcoma; Insulinoma; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Meningioma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma; Sarcoma, Ewing; Solid tumours; Somatostatinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms
Details
Nintedanib EsylateBIBF-1120ApprovedC.H. Boehringer Sohn Ag & Co. KgOfev, VargatefUnited StatesIdiopathic Pulmonary FibrosisBoehringer Ingelheim International Gmbh2014-10-15Adenocarcinoma, Clear Cell; Appendiceal Neoplasms; Asbestosis; Astrocytoma; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Endometrial Stromal Tumors; Esophageal Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Leukemia, Myeloid, Acute; Lung Diseases, Interstitial; Mesothelioma; Multiple Myeloma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Pulmonary Fibrosis; Radiation Pneumonitis; Rejection of lung transplantation; Sarcoma; Scleroderma, Systemic; Silicosis; Small Cell Lung Carcinoma; Solid tumours; systemic sclerosis-associated interstitial lung disease; Telangiectasia, Hereditary Hemorrhagic; Uterine Neoplasms
Details
FutibatinibTAS-120ApprovedOtsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co LtdLYTGOBIUnited StatesCholangiocarcinomaTaiho Oncology Inc2022-09-30Biliary Tract Neoplasms; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Lymphoma; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms
Details
SelpercatinibLOXO-292; LY-3527723; ARRY-192; Ret-IN-1ApprovedArray BiopharmaRetevmo, Retsevmo, 睿妥United StatesMedullary thyroid cancer (MTC); Thyroid Neoplasms; Carcinoma, Non-Small-Cell LungEli Lilly And Company2020-05-08Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Ependymoma; Fibrosarcoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medullary thyroid cancer (MTC); Medulloblastoma; Myofibromatosis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Poorly Differentiated Thyroid Gland Carcinoma; Renal Insufficiency; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Wilms Tumor
Details
PemigatinibINCB-054828; INCB-54828; IBI-375ApprovedIncyte CorpPemazyre, 伯坦, 达伯坦United StatesCholangiocarcinomaIncyte Corp2020-04-17Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colitis, Ulcerative; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myeloproliferative Disorders; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Translocation, Genetic; Urinary Bladder Neoplasms; Urologic Neoplasms
Details
TasurgratinibE-7090ApprovedEisai Co LtdTASFYGOJapanBiliary Tract NeoplasmsEisai Co Ltd2024-09-24Biliary Tract Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Hepatic Insufficiency; Neoplasms; Solid tumours
Details
Erdafitinib890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210ApprovedAstex Pharmaceuticals IncBalversa, 博珂United StatesCarcinoma, Transitional CellJanssen Biotech Inc2019-04-12Adenocarcinoma; Bile Duct Neoplasms; Bone metastases; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Ependymoma; Esophageal Neoplasms; Glioma; Hepatic Insufficiency; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland